MX2013011884A - Composiciones farmaceuticas de liberacion modificada de desvenlafaxina. - Google Patents

Composiciones farmaceuticas de liberacion modificada de desvenlafaxina.

Info

Publication number
MX2013011884A
MX2013011884A MX2013011884A MX2013011884A MX2013011884A MX 2013011884 A MX2013011884 A MX 2013011884A MX 2013011884 A MX2013011884 A MX 2013011884A MX 2013011884 A MX2013011884 A MX 2013011884A MX 2013011884 A MX2013011884 A MX 2013011884A
Authority
MX
Mexico
Prior art keywords
modified release
desvenlafaxine
release pharmaceutical
pharmaceutical compositions
relates
Prior art date
Application number
MX2013011884A
Other languages
English (en)
Inventor
Ashok Kumar Sahoo
Shrenik Kole
Makrand Avachat
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2013011884A publication Critical patent/MX2013011884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas de liberación modificada que comprenden desvenlafaxina, uno o más agentes modificadores de liberación y uno o más excipientes farmacéuticamente aceptables de los mismos. Más en particular, la invención se relaciona con composiciones farmacéuticas de liberación modificada que comprenden benzoato de desvenlafaxina y un proceso para la preparación de las mismas. Además, la invención se relaciona con una composición farmacéutica de liberación modificada que comprende benzoato de desvenlafaxina, uno o más agentes modificadores y uno o más excipientes farmacéuticamente aceptables de los mismos en donde la Cmax y el AUC de la composición de liberación modificada son independientes del efecto de los alimentos.
MX2013011884A 2011-04-12 2012-04-11 Composiciones farmaceuticas de liberacion modificada de desvenlafaxina. MX2013011884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN530KO2011 2011-04-12
PCT/IB2012/051761 WO2012140577A1 (en) 2011-04-12 2012-04-11 Modified release pharmaceutical compositions of desvenlafaxine

Publications (1)

Publication Number Publication Date
MX2013011884A true MX2013011884A (es) 2013-11-21

Family

ID=46062650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011884A MX2013011884A (es) 2011-04-12 2012-04-11 Composiciones farmaceuticas de liberacion modificada de desvenlafaxina.

Country Status (5)

Country Link
KR (1) KR20140030156A (es)
AU (1) AU2012241407B2 (es)
BR (1) BR112013025766A2 (es)
MX (1) MX2013011884A (es)
WO (1) WO2012140577A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104352469A (zh) * 2014-11-20 2015-02-18 哈尔滨圣吉药业股份有限公司 一种琥珀酸去甲文拉法辛缓释片及其制备方法
TR201820634A2 (tr) * 2018-12-27 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Desvenlafaksi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US6197828B1 (en) 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
DK1466889T3 (da) 1999-04-06 2008-09-08 Sepracor Inc O-Desmethylvenlafaxin-succinat
KR100875610B1 (ko) 2001-02-12 2008-12-26 와이어쓰 Ｏ-데스메틸-벤라팍신의 신규한 석시네이트 염
KR20050013125A (ko) 2002-06-10 2005-02-02 와이어쓰 Ｏ-데스메틸-벤라팍신의 신규한 포르메이트 염
CA2554559A1 (en) 2004-02-06 2005-08-25 Wyeth Multiparticulate o-desmethylvenlafaxine salts and uses thereof
MX2007012167A (es) * 2005-03-31 2007-11-22 Wyeth Corp Producto de combinacion de o-desmetilvenlafaxina y bazedoxifeno, y usos del mismo.
AU2006270315A1 (en) 2005-07-15 2007-01-25 Wyeth Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
US7820716B2 (en) 2007-01-08 2010-10-26 Mai De Ltd Crystalline polymorphs of desvenlafaxine succinate and their preparations
US20100210719A1 (en) 2007-07-12 2010-08-19 Dr. Reddy's Laboratories Ltd. O-desmethylvenlafaxine
WO2009017813A1 (en) 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
WO2009049354A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US20110046231A1 (en) 2007-10-22 2011-02-24 Actavis Group Ptc Ehf Solid forms of (±)-o-desmethylvenlafaxine salts
EP2085377A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Novel salts of O-desmethyl-venlafaxine
KR100965527B1 (ko) 2008-05-08 2010-06-23 제일약품주식회사 신규(4-(2-(디메틸아미노)-1-(1-하이드록시사이클로헥실)에틸)페녹시)포스페이트 또는 이의 약학적으로 허용가능한 염,이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계질환 예방 및 치료용 조성물
KR20100132069A (ko) 2008-06-16 2010-12-16 테바 파마슈티컬 인더스트리즈 리미티드 Ｏ-데스메틸벤라팍신염의 고체 상태

Also Published As

Publication number Publication date
NZ609568A (en) 2015-10-30
AU2012241407A1 (en) 2013-05-02
AU2012241407B2 (en) 2015-02-05
BR112013025766A2 (pt) 2016-12-20
KR20140030156A (ko) 2014-03-11
WO2012140577A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
MX2013001677A (es) Formulaciones estables de linaclotida.
WO2011130615A3 (en) Preparation of lacosamide
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX342807B (es) Cocristales farmacéuticamente aceptables de n- [2-(7-metoxi-1-naftil) etil] acetamida y métodos para su preparación.
WO2010092090A3 (en) Novel salts of sitagliptin
MX2013000642A (es) Composiciones farmaceuticas.
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
MX2014004196A (es) Citramida de rasagilina.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010049449A3 (en) Novel salts of sunitinib
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
EP2722042A4 (en) INDANONE DERIVATIVES, THEIR OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES
MD4563C1 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
AU2012277905A8 (en) Topical ophthalmological pharmaceutical composition containing regorafenib
WO2011089126A3 (en) Novel retigabine composition
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
WO2011064558A3 (en) Pharmaceutical composition
WO2014006636A3 (en) Stable compositions of fesoterodine
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
MX2013011884A (es) Composiciones farmaceuticas de liberacion modificada de desvenlafaxina.
CO6721030A2 (es) Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartan y método para la preparación de la misma